# Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

> **NCT02614846** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 29 (estimated)

## Conditions studied

- Chronic Idiopathic Thrombocytopenic Purpura

## Interventions

- **DRUG:** Hetrombopag Olamine

## Key facts

- **NCT ID:** NCT02614846
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2016-03
- **Final completion:** —
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2015-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614846, "Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02614846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*